Ixekizumab for the treatment of ankylosing spondylitis
Volume: 16, Issue: 8, Pages: 745 - 750
Published: Aug 2, 2020
Abstract
Introduction Ixekizumab (IXE) is a high affinity IgG4 approved for the treatment of ankylosing spondylitis (AS). Recently, two phase III randomized clinical trials (COAST-V, COAST-W) showed significant and sustained improvements in signs and symptoms of AS as evaluated by ASAS40 response. Areas covered: The authors performed a comprehensive literature search on this topic, by a review of published articles to date. The authors introduced the...
Paper Details
Title
Ixekizumab for the treatment of ankylosing spondylitis
Published Date
Aug 2, 2020
Volume
16
Issue
8
Pages
745 - 750
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History